Microscope image of green plant cells with chloroplasts

Pharma portfolio strategy

Act with speed and confidence in your portfolio decisions with objective, science-driven portfolio management consulting spanning due diligence to asset positioning.

Start the conversation
Pattern=Portfolio & BD Support

Clarity for complex business decisions

Pharma portfolio strategy often misfires due to noise, bias, and uncertainty. Our PhD-trained team combines scientific analysis, business acumen, and validated biopharma-specific AI to strip away clutter so you can confidently move forward.
>100 due diligences performed
We provided strategic advice on deals covering (pre-)clinical and regulatory aspects
84% trial prediction accuracy
We predicted clinical efficacy trial outcomes with 84% accuracy
Multi-billion value generation
Our portfolio strategies have led to transacted assets worth billions

Asset search and evaluation

Cut through a vast asset landscape to find what's worth pursuing. Screen 100k+ biopharma NMEs and 20k companies worldwide with AI-enabled real-time, continuous monitoring and analysis that transcends language barriers. Our validated approach has led to numerous successful deals and multi-billion-dollar value generation.
View Flyer
Microscopic image of fluorescently stained fibroblasts

Drug due diligence consulting

Move quickly in competitive processes without overlooking critical details. Our collaborative, systematic approach to technical and commercial due diligence is comprehensive across all relevant dimensions, while remaining efficient and fast. We coordinate Q&A and support deal structuring based on identified risks, so you can commit to the right deals with confidence.
Close up of a scientist's gloved hands adjusting a sample on a microscope

Asset positioning support

Give partners the information they need to make a decision, framed in the way that’s most likely to land. We anticipate potential questions and prepare marketing materials, including decks, that address partner concerns and highlight asset differentiation, increasing the chance of a successful transaction.
View service flyer
Microscopic image of crystals under polarized light

Success story: driving 15x share-price growth

Portfolio management challenge

A mid-sized biotech was struggling with pipeline setbacks that put both growth plans and investor confidence at risk. The team needed to secure new opportunities quickly to restore momentum and credibility.

Scitaris solution

Scitaris deployed our science-driven asset search and evaluation framework, drawing on proprietary algorithms and curated databases to scan more than 70,000 programs worldwide.

Results

Within weeks, the company licensed a high-value program that revitalized its portfolio and reassured stakeholders. The strengthened pipeline supported critical decision-making and contributed to a 15-fold increase in share price over the following year.

Phase contrast image of neurons in cell culture

What our clients say

Joe Truitt
Joe Truitt
CEO, iECURE Inc. (former CEO, Achillion Pharma Inc. & Biospecifics Technologies Inc.)

The Scitaris team were tremendous partners in our efforts to evaluate new business opportunities to add to our product portfolio.

Their insight across all of the critical segments – scientific data, clinical path, regulatory, commercial, competitive landscape – made the process efficient and productive for our Management team. I would recommend this group for anyone needing to make strategic additions to their company offerings.

Matt Call
Matt Call
COO, iTeos Therapeutics Inc.

Over the last years, I have had the pleasure to work with Scitaris on some key strategic projects for our firm and was, without exception, extremely impressed by the exceptional quality of the firm's work.

They never relied on ‘off the shelf solutions’ for challenges but unceasingly came up with innovative and tailor-made approaches, in all cases adding real value to the company. This, coupled with his exceptionally high standards of quality, deep industry knowledge and strong managerial skills, positions Scitaris as one of the top advisors in the industry.

Jesse Shefferman
Jesse Shefferman
CEO, Protara Therapeutics

Scitaris is an extraordinary team that combines rigorous scientific diligence with a robust understanding of the biopharma market to provide us [Protara] with valuable insights. Over our many years of working with them, they have proved time and again that they are trusted thought partners for our business development efforts.

Mike Andriole
Mike Andriole
CFO & CBO, Chimerix Inc. (former CBO, Endocyte Inc.)

Scitaris’ intellect and passion for the work is remarkable.

Moreover, it is not every day you get to work with talented people that you really enjoy being in their company and interacting on a daily basis — this is certainly true with all of the team.

Section Divider

FAQs

What is the overall process, and how customizable is it?

Our PHD-led opportunity screens are augmented by Scitaris-AI, an agentic framework built on our validated consulting methodology.

First, we tailor the agent: decision criteria, competitive benchmarks, and transactability thresholds are set against your therapeutic focus, geographic priorities, deal structure, and portfolio gaps. Scitaris-AI then assesses and ranks the entire opportunity space with ~95% accuracy and ~94% reproducibility. Real-time continuous news and data integration gives us an up-to-the-minute market picture, and foreign news integration erodes any language barriers.

PhD-level consultants then validate the output, interpreting results, handling edge cases, and applying critical judgment for final recommendations. The result is a prioritized asset option space, analyzed at varying levels of depth to focus on the best opportunities. The process is fully customizable throughout.

Can we include side entries in the analysis?

Yes. Side entries and inbound lists from investment banks can be integrated at any stage.

How does pricing work? Do you offer success-based or project-based fees?

We invoice only for the actual effort spent, without success-based fees, to ensure full objectivity for our clients.

How long does a typical engagement take?

Depending on scope, projects range from under a week for a single-asset analysis to about two months for a full end-to-end opportunity screen.

Looking for other information?
We’re happy to help.

Ask a question

Featured Insights

See All News & Events
See all resources
White Papers

Biopharma asset search & evaluation: Confidence amid the fog of data-rich information

Biopharma asset search & evaluation: Confidence amid the fog of data-rich information
Scitaris-AI: A biopharma-specific LLM agent
Articles

Scitaris-AI: A biopharma-specific LLM agent
Asset Search: turning crisis into a 9-digit comeback
Case Studies

Asset Search: turning crisis into a 9-digit comeback
See All News & Events
See all resources

Facing a complex portfolio decision?

Let’s help you get it right